<h1>Shareholder value: longstanding NSE listing highlights sustained revenue and profit growth and substantial investor returns.</h1> Listing on the National Stock Exchange: Zydus Lifesciences Ltd. commemorated its twenty fifth year of continuous NSE listing, noting sustained long term growth in revenue, operating profit, and profit after tax, and reporting significant investor returns from its IPO when adjusted for dividends and buybacks; the event featured senior management and NSE representatives as part of corporate disclosure and market engagement.